How the Wegovy dosage plan works — and what that means for you

Why the dose escalation exists, and what you're actually deciding at each step

Every stage of the Wegovy schedule involves a quiet clinical decision: stay or move up. Your prescriber makes that call based on how you're tolerating the current dose, not on a calendar alone. The four-week minimum at each step allows the GI effects (nausea, loose stools, reflux) to settle before adding more semaglutide. Rushing this window is where side effects tend to compound rather than resolve.

The five steps are 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg weekly. Some people stay longer at a given step if tolerance is an issue; some reach 2.4 mg and find it sufficient for the duration. The full dose breakdown covers what changes at each level physiologically, but the short version is that appetite suppression and gastric-emptying effects increase progressively. None of this is linear for every person.

The MHRA-approved 7.2 mg single-dose pen, cleared in April 2026, adds a further option for adults with a BMI of 30 or above who have been titrated up through the standard schedule. That decision sits entirely with the prescriber, not something to raise as a preference before you've completed the standard escalation. The maximum dose page explains the 7.2 mg approval in detail.

The starter dose: what 0.25 mg does and doesn't do

People sometimes feel discouraged at 0.25 mg because appetite change is minimal. This is not a sign the medicine isn't working; it's a sign the schedule is working exactly as intended. The body needs time to adjust to semaglutide before a therapeutic effect becomes apparent. According to the NHS semaglutide medicines page, the 0.25 mg and 0.5 mg doses are introductory steps, weight-management outcomes are associated with the higher maintenance doses.

The 0.25 mg stage typically lasts four weeks. After that, if you're tolerating the injections well, your prescriber will move you to 0.5 mg. Injection site rotation (abdomen, thigh, upper arm) matters from the first dose; reactions are less likely when sites are varied consistently. Store your pens in the fridge at 2–8°C and refer to your Patient Information Leaflet for the precise room-temperature window; the exact duration permitted outside refrigeration is there in black and white.

One thing our prescribers hear regularly: people who take the low-dose phase seriously tend to have a smoother experience at 1.7 mg and 2.4 mg. Treating the early steps as disposable is a common mistake.

Reaching and staying on the maintenance dose

The 2.4 mg weekly injection is the licensed maintenance dose for weight management, the level at which the STEP 1 trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% over 68 weeks in adults without diabetes. That figure is a trial average across a large population; individual results vary, and a prescriber will review progress regularly. Staying on the maintenance dose long-term requires periodic clinical re-review, not just continued supply.

NICE's appraisal of semaglutide (TA875) recommends the medicine for a maximum of two years when used within a specialist weight management service, a detail worth reading if you're planning beyond the first year. For private treatment, the prescriber's own review process applies, but the underlying evidence still shapes clinical decision-making.

If side effects at 2.4 mg are persistent rather than settling, your prescriber may suggest holding at 1.7 mg for longer. That's a legitimate clinical route, the titration ladder isn't strictly one-way. Missing a dose for more than a set number of days may mean restarting at a lower step; the Patient Information Leaflet sets out the guidance, and your prescriber can clarify. For a broader overview of the Wegovy treatment, including how it compares to other licensed options, the main pillar page covers the wider picture. If cost is a factor in your thinking, the Wegovy cost page breaks down what private treatment typically involves.

Practical factors that affect how your dosage plan lands in real life

Timing consistency matters more than most people realise. Taking your injection on the same day each week, within a reasonable window, keeps semaglutide levels stable. Shifting injection day by a day or two occasionally is generally fine (the SmPC and your prescriber can advise on the exact flexibility) but erratic timing across weeks disrupts the steady-state concentration the plan depends on.

Diet and activity interact with the plan in ways the schedule alone can't account for. Appetite is suppressed, often significantly at higher doses, which means protein intake and hydration need attention. Eating smaller meals more slowly reduces nausea at dose-transition points. These aren't optional lifestyle tips; they're the practical support that makes the medicine work rather than just be tolerated.

The pen and dosing mechanics page covers how each Wegovy pen is set up and used, useful if you're approaching your first injection or moving to a new dose pen format. For any questions about your specific situation, the free consultation is the right place to start: a GPhC-registered prescriber, not an automated system, reviews your case the same day.